Volume 11, Number 10—October 2005
Research
Vancomycin and Home Health Care
Thomas G. Fraser*1, Valentina Stosor*, Qiong Wang†, Anne Allen‡, and Teresa R. Zembower*
Table 4
Infection diagnoses in patients referred for home infusions of vancomycin
| Diagnosis* | Use per guidelines, no. (%), N = 180 | Use outside guidelines, no. (%), N = 116 | p value† |
|---|---|---|---|
| Skin or soft tissue infection | 89 (49.4) | 51 (44.0) | 0.356 |
| Osteomyelitis or septic arthritis | 30 (16.7) | 25 (21.6) | 0.294 |
| Postoperative wound infection | 38 (21.1) | 19 (16.4) | 0.310 |
| Orthopedic device-related infection | 5 (2.8) | 7 (6.0) | 0.227 |
| Central nervous system infection‡ | 3 (1.7) | 6 (5.2) | 0.161 |
| Urinary tract infection | 36 (20.0) | 13 (11.2) | 0.042 |
| Pneumonia | 9 (5.0) | 1 (0.9) | 0.095 |
| Bloodstream infection | 61 (33.9) | 16 (13.8) | <0.001 |
| Vascular device infection | 21 (11.7) | 10 (8.6) | 0.398 |
| Infective endocarditis | 8 (4.4) | 5 (4.3) | 0.956 |
*Some patients had >1 diagnosis.
†Values <0.05 were considered significant.
‡Includes shunt infections.
1Current affiliation: Cleveland Clinic Foundation, Cleveland, Ohio, USA
Page created: February 22, 2012
Page updated: February 22, 2012
Page reviewed: February 22, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.